This company presentation of Isofol Medical AB (publ) ("Isofol") has been prepared for advertisement purposes. It is not a prospectus and has not been prepared in accordance with the prospectus requirements in the Swedish Financial Instruments Trading Act (lagen (1991:980) om handel med finansiella instrument) or the European prospectus regulation (809/2004/EC) (the "Prospectus Regulations"). This company presentation is not subject to any registration or approval requirements under the Prospectus Regulations and has not been, and will not be, examined, approved or registered by the Swedish Financial Supervisory Authority or any financial supervisory authority or other supervisory body within the EU.
The company presentation may not be forwarded, reproduced or made available in or into any jurisdiction in which such publication or distribution would require any additional documentation to be prepared or registration effected or that any measures are taken in addition to those required under Swedish law or where it would be in conflict with any law or regulation in such jurisdiction. Persons who come into possession of this document are required to inform themselves about, and to observe, such restrictions.
The courts of Sweden shall have exclusive jurisdiction over any dispute arising out of or in connection with this document company presentation and the City Court of Gothenburg, Sweden, shall be the court of first instance.
Isofol was founded in 2008 in Gothenburg, secured funding of an additional MSEK 452 in June 2021 and listed on Nasdaq Stockholm in October 2021
Isofol develops arfolitixorin for the treatment of colorectal cancer (CRC), the third most common cancer type
Since 2013 Isofol have strategic CMC partnerships with Merck & Cie and Recipharm
Isofol has two strategic licensing agreements from 2020 with Solasia Pharma KK in Japan and Endo/Paladin in Canada
Late stage fully recruited phase III study with Top-Line results estimated during H1 2022
Pre-commercialization activities initiated, including the development of medical affairs and commercial launch packages
Shareholders
Number of
Capital/Votes
shares
(%)
Futur Pension
13,335,256
8.26%
Avanza Pension
7,927,068
4.91%
Handelsbanken Fonder
5,938,471
3.68%
Nordnet Pensionsförsäkring
5,433,172
3.36%
Swedbank Försäkring
5,268,567
3.26%
Hans Enocson
4,555,236
2.82%
Fjärde AP-fonden
4,521,257
2.80%
Swedbank Robur Fonder
4,175,839
2.59%
Bengt Gustafsson*
3,749,459
2.32%
Peak Asset Management
3,381,964
2.09%
10 larges share owners
58,286,289
36.09%
Other owners
103,229,111
63.91%
TOTAL
161,151,440
100%
Number of shareholders approx. 4500
Source: The list of Isofol´s largest shareholders is based on information from Euroclear Sweden AB as of 30 September 2021. * Own or related natural or legal person holding shares (direct and indirect) and other financial instruments in the company
Isofol Medical AB published this content on 08 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 December 2021 14:51:02 UTC.
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
